Application of epilupinine and derivative thereof in preparation of medicine for treating depression

Abstract

The invention provides application of epilupinine (1-EPILLUPININE) and a derivative of the epilupinine (1-EPILLUPININE) in preparation of a medicine for treating depression. The application dosage is 0.01-30 mg of epilupinine or the derivative thereof per kilogram of body weight, and the anti-depression effect can be achieved within 60 minutes after administration. After the medicine is administrated for 5 days, the obvious anti-depression effect is generated in the low dosage and the high dosage. Research results show that in a mammal mouse tail suspension experiment, the epilupinine or the derivative thereof has a rapid anti-depression effect, and is more effective than a conventional anti-depression drug imipramine. According to the method, a forced swimming experiment and a mouse tail suspension experiment are adopted as drug screening experiments, and meanwhile, an Open field test is carried out, so that the autonomous activity of a mouse is detected, and interference of central excitants is avoided. The anti-depression drug has the advantages of being remarkable in anti-depression effect, quick in effect taking, small in dosage, small in side effect and the like, and is expected to become a new anti-depression drug which is quick, efficient and novel in mechanism.

Description

technical field [0001] The invention belongs to the technical field of medicine, and relates to the application of epilupinine (1-EPILUPININE) and derivatives thereof in the preparation of drugs for treating depression and the prepared antidepressant drugs. Background technique [0002] Major depressive disorder (MDD) is a severe, recurrent and disabling mental illness that affects approximately 300 million people worldwide. The incidence of depression in China is 4.2%, and there are about 56 million people with depression. Depression is the second leading cause of life lost (years) due to disability and has become a major public health problem that needs to be addressed urgently. Depression can be seen clinically as low mood, emotional depression, low self-esteem and depression, and even pessimism and world-weariness, and there may be suicide attempts or behaviors. The current clinical first-line antidepressants mainly include selective serotonin reuptake inhibitors, sero...

AI Technical Summary

Problems solved by technology

Patients with such treatment-resistant depression have a higher risk of social burden and suicide risk

So far, there has been no report of epi-lupine as an active ingredient in the prevention or treatment of depression

Images